Anti-myelin-associated glycoprotein neuropathy
- 1 October 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Neurology
- Vol. 19 (5), 458-463
- https://doi.org/10.1097/01.wco.0000245368.36576.0d
Abstract
The anti-myelin-associated glycoprotein (MAG) neuropathy is an antibody-mediated demyelinating neuropathy. The clinical picture is characterized by a distal and symmetric, mostly sensory neuropathy. Monoclonal immunoglobulin M anti-MAG antibodies are uniquely found in this condition and are believed to be pathogenic. This review focuses on recent progress in understanding the mechanisms of this neuropathy and discusses new therapeutic advances. Different electrophysiological parameters have been demonstrated to distinguish the anti-MAG-associated polyneuropathy from chronic inflammatory demyelinating polyneuropathy. The electrophysiological findings generally indicate a predominantly demyelinating neuropathy with a distal accentuation of conduction slowing. Analyses of pathology in nerve tissue from anti-MAG patients using classical nerve biopsy or skin biopsy tissue demonstrated immunoglobulin M deposits at the site of MAG localization, demyelination and axonal degeneration. MAG is a Schwann cell-based glycoprotein and has been implicated as a mediator of an outside-in signaling cascade influencing the cytoskeletal integrity of axons. Therapy in patients with anti-MAG neuropathy is directed at reducing the antibody concentration, blocking the effector mechanisms and depleting the monoclonal B cells. The recent availability of rituximab, a monoclonal antibody suppressing B-cell clones, which is not myelosuppressive and does not cause secondary malignancies, allows for early targeted intervention.This publication has 39 references indexed in Scilit:
- Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studiesActa Neurologica Scandinavica, 2009
- High-dose rituximab and anti-MAG–associated polyneuropathyNeurology, 2006
- Distal motor latency and residual latency as sensitive markers of anti-MAG polyneuropathyZeitschrift für Neurologie, 2003
- Treatment of IgM antibody associated polyneuropathies using rituximabJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Can electrophysiology differentiate polyneuropathy with anti-MAG/SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?Clinical Neurophysiology, 2002
- Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathiesClinical Neurophysiology, 2001
- Distal acquired demyelinating symmetric neuropathyNeurology, 2000
- The Spectrum of IgM Monoclonal Gammopathy in 430 CasesMayo Clinic Proceedings, 1987
- Demyeliating neuropathy and monoclonal IgM antibody to myelin‐associated glycoproteinNeurology, 1983
- Myelin‐Associated Glycoprotein Is the Antigen for a Monoclonal IgM in PolyneuropathyJournal of Neurochemistry, 1982